LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 26

Search options

  1. Article ; Online: Can the Glasgow prognostic score predict ischemic stroke in patients with infective endocarditis?

    Aydın, Cihan / Demirkıran, Aykut / Aykaç, Hüseyin / Uslu, Nurullah / Alpsoy, Şeref

    Revista da Associacao Medica Brasileira (1992)

    2024  Volume 70, Issue 3, Page(s) e20231299

    Abstract: Objective: The Glasgow prognosis score is a simple parameter calculated using serum levels of albumin and C-reactive protein. The aim of this study was to examine whether this parameter may predict ischemic stroke in patients with infective endocarditis. ...

    Abstract Objective: The Glasgow prognosis score is a simple parameter calculated using serum levels of albumin and C-reactive protein. The aim of this study was to examine whether this parameter may predict ischemic stroke in patients with infective endocarditis.
    Methods: A total of 80 patients who were diagnosed with definitive infective endocarditis according to Duke criteria between 2016 and 2023 were included in the study. Glasgow prognosis score was based on serum levels of albumin and C-reactive protein. In imaging methods, patients were divided into two groups according to whether they had a stroke or not. These two groups were compared in terms of biochemical parameters, and infective endocarditis findings on echocardiography and Glasgow prognosis score.
    Results: We found that the results were statistically similar except for serum C-reactive protein (Group 1: 54.9±71.1 and Group 2: 39±70.7; p=0.03), neutrophil (Group 1: 19.8±10.8*109/L and Group 2: 13.3±7.3*109/L; p=0.014), albumin (Group 1: 2.3±0.6 and Group 2: 2.8±0.5; p=0.03), and Glasgow prognosis score (Group 1: median 2, min.-max. (1-2) and Group 2: median 1, min.-max. (0-1); p=0.004). In the receiver operating characteristics analysis, Glasgow prognosis score had 82.4% sensitivity and 58.3% specificity in predicting ischemic stroke if the Glasgow prognosis score cutoff was ≥1. In multivariate logistic regression analysis, chronic renal failure [odds ratio (OR): 1.098; 95% confidence interval: 1.054-1.964; p=0.044], age (OR: 1.050; 95%CI 1.006-1.096; p=0.024), and Glasgow prognosis score (OR: 0.695; 95%CI 0.411-0.949; p=0.035) were independent variables in predicting ischemic stroke.
    Conclusion: High Glasgow prognosis score is an independent predictor of ischemic stroke in patients with infective endocarditis. Glasgow prognosis score, determined using albumin and C-reactive protein levels, is a simple and practical index for predicting the prognosis of patients hospitalized with infective endocarditis.
    MeSH term(s) Humans ; Female ; Male ; C-Reactive Protein/analysis ; Prognosis ; Middle Aged ; Ischemic Stroke/blood ; Ischemic Stroke/complications ; Serum Albumin/analysis ; Aged ; Endocarditis/blood ; Endocarditis/complications ; Adult ; Echocardiography ; Biomarkers/blood ; Risk Factors ; Predictive Value of Tests
    Chemical Substances C-Reactive Protein (9007-41-4) ; Serum Albumin ; Biomarkers
    Language English
    Publishing date 2024-04-22
    Publishing country Brazil
    Document type Journal Article
    ZDB-ID 731969-1
    ISSN 1806-9282 ; 0104-4230 ; 0004-5241 ; 0102-843X
    ISSN (online) 1806-9282
    ISSN 0104-4230 ; 0004-5241 ; 0102-843X
    DOI 10.1590/1806-9282.20231299
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 654: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Role of simple inflammatory parameters in predicting the severity of coronary artery disease.

    Aydın, Cihan / Uyan, Umut / Karadeniz, Muhammed / Demirkıran, Aykut

    Revista da Associacao Medica Brasileira (1992)

    2023  Volume 69, Issue 11, Page(s) e20230518

    Abstract: Objective: In our study, we aimed to find simple, useful biomarkers in patients with non-ST elevation myocardial infarction to predict coronary artery severity.: Methods: Between May 2022 and December 2022, patients diagnosed with non-ST elevation ... ...

    Abstract Objective: In our study, we aimed to find simple, useful biomarkers in patients with non-ST elevation myocardial infarction to predict coronary artery severity.
    Methods: Between May 2022 and December 2022, patients diagnosed with non-ST elevation myocardial infarction according to the European cardiology guidelines were included in our study. The Synergy between PCI with Taxus and Cardiac Surgery score was calculated to determine the severity of coronary artery disease. These patients were classified into two groups according to Synergy between PCI with Taxus and Cardiac Surgery≥23 and Synergy between PCI with Taxus and Cardiac Surgery<23 scores. Biochemical markers such as platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio were studied in blood tests taken before coronary angiography in patients diagnosed with non-ST elevation myocardial infarction according to current guidelines. These two groups were compared in terms of the data obtained.
    Results: There were 281 patients in group 1 and 67 patients in group 2. There was no significant difference between the two groups in terms of demographic data such as age and gender. Platelet-to-lymphocyte ratio [group 1=125 (26-134) and group 2=156 (73-293); p=0.001] and neutrophil-to-lymphocyte ratio [group 1=2.71 (1.3-30.2) and group 2=3.2 (2.1-32.1); p=0.002] were higher in the group of patients with a Synergy between PCI with Taxus and Cardiac Surgery score of <23, while lymphocyte-to-monocyte ratio [group 1=3.6 (0.56-11) and group 2=3.4 (0.64-5.75); p=0.017] was lower in group 2.
    Conclusion: We observed that elevated platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios showed coronary artery severity. Multivessel disease and chronic total occlusion rates were observed to be higher in patients with high platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios.
    MeSH term(s) Humans ; Coronary Artery Disease/surgery ; Percutaneous Coronary Intervention ; Risk Factors ; Coronary Angiography ; Non-ST Elevated Myocardial Infarction
    Language English
    Publishing date 2023-10-09
    Publishing country Brazil
    Document type Journal Article
    ZDB-ID 731969-1
    ISSN 1806-9282 ; 0104-4230 ; 0004-5241 ; 0102-843X
    ISSN (online) 1806-9282
    ISSN 0104-4230 ; 0004-5241 ; 0102-843X
    DOI 10.1590/1806-9282.20230518
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 654: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Twelve-Month Outcomes of a Novel Iopromide-Based Paclitaxel-Coated Balloon for the Treatment of Chronic Total Occlusion of Femoropopliteal Arteries.

    Özpak, Halil Berkan / Aydın, Cihan / Demirkıran, Aykut

    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir

    2023  Volume 51, Issue 2, Page(s) 112–118

    Abstract: Objective: We designed a retrospective study to evaluate the performance and outcomes of a novel iopromide-based paclitaxel-coated balloon for the treatment of chronic total occlusion of femoropopliteal arteries.: Methods: Patients with ... ...

    Title translation Femoro-popliteal Arterlerdeki Kronik Total Oklüzyon Tedavisinde İopromid Bazlı Paklitaksel Kaplı Balonun On İki Aylık Sonuçları.
    Abstract Objective: We designed a retrospective study to evaluate the performance and outcomes of a novel iopromide-based paclitaxel-coated balloon for the treatment of chronic total occlusion of femoropopliteal arteries.
    Methods: Patients with femoropopliteal chronic total occlusion (<100 mm) on angiogram were screened from hospital management system and were included in the study. The width and length of the drug-eluting peripheral balloon was chosen to ensure a vessel/balloon ratio of 1: 1 and exceed the lesion by 10 mm on both ends (based on visual estimation).
    Results: The proportion of patients with ankle-brachial index improvement was 89.8% (106 of 118). The mean ankle-brachial index was 0.5 (0.4-0.7) at baseline and 0.8 (0.7-0.9) at 12 months (P < 0.001). Changes in the Rutherford category between baseline and 12 months were statistically significant (P < 0.001), with the majority of patients (77.9%, 92/118) having ≥1 level improvement. The rate of clinically driven target lesion revasculariza-tion at 12 months was 13.5%(16/118). Overall, the 1-year primary patency rate was 86.4% (102 of 118). The major adverse limb event rate was 9.8% (16/162). Acute limb ischemia was detected in 14 patients, and amputation was performed in 2 patients.
    Conclusion: Our study is a non-randomized clinical study focusing on the use of drug-eluting balloon as a single treatment strategy. There was significant clinical benefit to patients, as clearly demonstrated by the improvement in ankle-brachial index and the reduction in Rutherford class in the short term, and these results may offer clear insights on the revascularization strategy outlook of interventionalists.
    MeSH term(s) Humans ; Popliteal Artery ; Paclitaxel/therapeutic use ; Retrospective Studies ; Treatment Outcome ; Peripheral Arterial Disease/therapy ; Angioplasty, Balloon/methods ; Femoral Artery ; Cardiovascular Agents/adverse effects
    Chemical Substances Paclitaxel (P88XT4IS4D) ; iopromide (712BAC33MZ) ; Cardiovascular Agents
    Language English
    Publishing date 2023-03-29
    Publishing country Turkey
    Document type Clinical Trial ; Journal Article
    ZDB-ID 1215217-1
    ISSN 1308-4488 ; 1016-5169
    ISSN (online) 1308-4488
    ISSN 1016-5169
    DOI 10.5543/tkda.2022.25324
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4156: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line.

    Korkmaz, Mustafa / Eryılmaz, Melek Karakurt / Koçak, Mehmet Zahid / Er, Muhammed Muhiddin / Hendem, Engin / Demirkıran, Aykut / Araz, Murat / Artaç, Mehmet

    European journal of clinical pharmacology

    2024  Volume 80, Issue 6, Page(s) 941–947

    Abstract: Purpose: Vascular endothelial growth factor (VEGF) inhibition is one of the cornerstones of treatment in the treatment of metastatic renal cell carcinoma (mRCC). Since RCC is a disease of advanced age and hypertension as a side effect of VEGF receptor ... ...

    Abstract Purpose: Vascular endothelial growth factor (VEGF) inhibition is one of the cornerstones of treatment in the treatment of metastatic renal cell carcinoma (mRCC). Since RCC is a disease of advanced age and hypertension as a side effect of VEGF receptor inhibitors, beta-blocker use is common in these patients. We aimed to compare the treatment efficacy and survival results in case of concomitant use of these two drugs due to the inhibition of VEGF in beta-blockers.
    Methods: A total of 121 patients with a diagnosis of mRCC who used sunitinib or pazopanib in first-line therapy were included in the study. These patients were divided into two groups as those using concomitant beta-blockers and those not using them.
    Result: The median overall survival (mOS) of the patient using sunitinib or pazopanib and concomitant beta-blocker was 47 (95% CI 29.0-65.0) months, and the mOS of those not using concomitant beta-blocker was 18 (95% CI 8.9-27.1) months (p < 0.001). The median progression-free survival (mPFS) of the patients using sunitinib or pazopanib and concomitant beta-blocker was 20.4 (95% CI 4.5-40.1) months, and the mPFS of those not using it was 11.4 (95% CI 5.9-16.9) months (p = 0.042). Concomitant beta-blocker use was found to be a good prognostic factor for OS in the multivariate analysis (p = 0.029). In the multivariate analysis, concomitant beta-blocker use had a trend towards statistical significance for PFS (p = 0.062).
    Conclusion: Concomitant use of betablockers with sunitinib or pazopanib is associated with longer overall survial and progression free survival.
    MeSH term(s) Humans ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/mortality ; Indazoles/therapeutic use ; Indazoles/adverse effects ; Indazoles/administration & dosage ; Male ; Female ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/mortality ; Kidney Neoplasms/pathology ; Sunitinib/therapeutic use ; Middle Aged ; Aged ; Sulfonamides/therapeutic use ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Pyrimidines/therapeutic use ; Pyrimidines/adverse effects ; Pyrimidines/administration & dosage ; Adrenergic beta-Antagonists/therapeutic use ; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors ; Progression-Free Survival ; Adult ; Aged, 80 and over ; Retrospective Studies ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/adverse effects
    Chemical Substances pazopanib
    Language English
    Publishing date 2024-03-13
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 121960-1
    ISSN 1432-1041 ; 0031-6970
    ISSN (online) 1432-1041
    ISSN 0031-6970
    DOI 10.1007/s00228-024-03668-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 672: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Investigation of the Relationship Between Triglycerides-Glucose İndex and Coronary Slow Flow: A Retrospective Case-Control Study.

    Kaplangoray, Mustafa / Toprak, Kenan / Başanalan, Fuat / Palice, Ali / Aydın, Cihan / Demirkıran, Aykut / Cekici, Yusuf

    Arquivos brasileiros de cardiologia

    2023  Volume 120, Issue 6, Page(s) e20220679

    Abstract: Background: Coronary slow flow (CSF) refers to delayed distal vessel opacification in the absence of epicardial coronary artery stenosis. The etiopathogenic mechanism of CSF is still unclear.: Objectives: This study investigates the relationship ... ...

    Title translation Investigação da Relação entre Índice de Triglicerídeos-Glicose e Fluxo Lento Coronariano: Um Estudo Retrospectivo de Caso-Controle.
    Abstract Background: Coronary slow flow (CSF) refers to delayed distal vessel opacification in the absence of epicardial coronary artery stenosis. The etiopathogenic mechanism of CSF is still unclear.
    Objectives: This study investigates the relationship between CSF and the triglyceride-glucose (TyG) index.
    Methods: The study sample consisted of 118 CSF patients and 105 patients with normal coronary flow (NCF). The coronary flow rate was measured via the Thrombolysis in Myocardial Infarction (TIMI) frame count (TFC) method in all patients. The TyG index was calculated as the logarithm of the [fasting triglyceride (mg/dL)×fasting glucose (mg/dL)]/2 value. A significance level of < 0.05 was adopted as statistically significant.
    Results: The TyG index, low-density lipoprotein (LDL), body mass index (BMI), neutrophil-to-lymphocyte ratio (NLR) and TFC values, male ratio, and the ratio of smokers were higher, whereas high-density lipoprotein (HDL) levels were significantly lower in the CSF group compared to the NCF group (p<0,05). The correlation analysis revealed that CSF was significantly correlated with TyG index, BMI, NLR, and HDL values. The strongest of these correlations was between CSF and TyG index (r= 0.57, p<0.001). Additionally, the multivariate analysis revealed that TyG index, BMI, NLR ratio, and male gender were independent predictors for CSF (p<0.05). Receiver operating characteristic (ROC) curve analysis indicated that a cut-off value of ≥ 9.28 for the TyG index predicted CSF with a sensitivity of 78% and a specificity of 78.1% [Area under the curve (AUC): 0.868 and 95% Confidence Interval (CI): 0.823-0.914].
    Conclusion: The findings of this study revealed a very strong relationship between CSF and TyG index.
    MeSH term(s) Humans ; Male ; Glucose ; Retrospective Studies ; Case-Control Studies ; Blood Glucose/analysis ; Triglycerides ; Biomarkers
    Chemical Substances Glucose (IY9XDZ35W2) ; Blood Glucose ; Triglycerides ; Biomarkers
    Language Portuguese
    Publishing date 2023-05-30
    Publishing country Brazil
    Document type Journal Article
    ZDB-ID 730261-7
    ISSN 1678-4170 ; 0066-782X
    ISSN (online) 1678-4170
    ISSN 0066-782X
    DOI 10.36660/abc.20220679
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 548: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Decrease of left ventricular ejection fraction in severe illness patients due to COVID-19 may improve as the disease resolves

    Demirkıran, Aykut / Onar, Lütfi Çağatay / Doğan, Mustafa

    Turkish journal of medical sciences

    2021  Volume 51, Issue 6, Page(s) 2861–2869

    MeSH term(s) Adult ; COVID-19/complications ; COVID-19/diagnosis ; Echocardiography ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Reverse Transcriptase Polymerase Chain Reaction ; SARS-CoV-2/genetics ; SARS-CoV-2/isolation & purification ; Severity of Illness Index ; Stroke Volume ; Troponin/blood ; Ventricular Dysfunction, Left/diagnostic imaging ; Ventricular Function, Left/physiology
    Chemical Substances Troponin
    Language English
    Publishing date 2021-12-13
    Publishing country Turkey
    Document type Journal Article
    ZDB-ID 1183461-4
    ISSN 1303-6165 ; 1300-0144
    ISSN (online) 1303-6165
    ISSN 1300-0144
    DOI 10.3906/sag-2101-198
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3242: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Nephrotic syndrome induced by cetuximab in a patient with metastatic colorectal cancer.

    Korkmaz, Mustafa / Hendem, Engin / Karakurt Eryılmaz, Melek / Demirkıran, Aykut / Karaağaç, Mustafa / Artaç, Mehmet

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

    2022  Volume 28, Issue 4, Page(s) 998–1002

    Abstract: Introduction: Cetuximab, an anti-EGFR monoclonal antibody, often cause skin toxicity, most commonly acneiform rash. We present a rare case of glomerulonephritis associated with cetuximab therapy.: Case report: A 58-year-old male patient recently ... ...

    Abstract Introduction: Cetuximab, an anti-EGFR monoclonal antibody, often cause skin toxicity, most commonly acneiform rash. We present a rare case of glomerulonephritis associated with cetuximab therapy.
    Case report: A 58-year-old male patient recently completed cetuximab-based chemotherapy for metastatic colorectal adenocarcinoma. He presented with acute renal failure, anasarca edema and nephrotic proteinuria. The amount of protein in the 24-h urine test was over 15.6 grams.
    Management & outcome: The patient showed a dramatic improvement in renal function shortly after terminated of cetuximab therapy without immunosuppressive therapy.
    Discussion: Therefore, drugs targeting epidermal growth factor receptor (EGFR) monoclonal antibody were thought to trigger nephrotic syndrome by causing glomerular damage. As a result, physicians using EGFR monoclonal inhibitors should be very careful about renal functions and proteinuria in patients.
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/adverse effects ; Cetuximab/adverse effects ; Colonic Neoplasms/drug therapy ; Colorectal Neoplasms/drug therapy ; ErbB Receptors ; Female ; Humans ; Male ; Middle Aged ; Nephrotic Syndrome/chemically induced ; Protein Kinase Inhibitors/therapeutic use ; Proteinuria ; Rectal Neoplasms/drug therapy
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents ; Protein Kinase Inhibitors ; ErbB Receptors (EC 2.7.10.1) ; Cetuximab (PQX0D8J21J)
    Language English
    Publishing date 2022-01-13
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 1330764-2
    ISSN 1477-092X ; 1078-1552
    ISSN (online) 1477-092X
    ISSN 1078-1552
    DOI 10.1177/10781552211073790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4488: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Low-dose (7.5 mg/kg) bevacizumab may be a viable option in recurrent ovarian cancer: A retrospective study.

    Demirkiran, Aykut / Eryilmaz, Melek Karakurt / Karaagac, Mustafa / Araz, Murat / Korkmaz, Mustafa / Koçak, Mehmet Zahid / Artac, Mehmet

    Journal of cancer research and therapeutics

    2023  Volume 19, Issue 3, Page(s) 595–600

    Abstract: Objective: Bevacizumab (BEV) is a humanized monoclonal antibody of vascular endothelial growth factor receptors and, as a result of clinical trials, was approved for the treatment of recurrent ovarian cancer (ROC). The aim of this study was to assess ... ...

    Abstract Objective: Bevacizumab (BEV) is a humanized monoclonal antibody of vascular endothelial growth factor receptors and, as a result of clinical trials, was approved for the treatment of recurrent ovarian cancer (ROC). The aim of this study was to assess the clinical utility of BEV in patients with ROC in real-world practice beyond clinical trials.
    Materials and methods: In this single-center retrospective cohort study, we evaluated the medical data of all patients with ROC who were treated with BEV between October 2013 and March 2020.
    Results: A total of 76 females were evaluated. Forty-nine (64.5%) patients were platinum sensitive and 27 (35.5%) patients were platinum resistant. BEV was used in combination with chemotherapy agents in all patients, and the most preferred combinations were gemcitabine/carboplatin (GC) (78.9%) and carboplatin/paclitaxel (14.5%). In all patients, the BEV dose was 7.5 mg/kg every 3 weeks. The median progression-free survival (PFS) was 11.1 months (95% confidence interval [CI]: 9.6-12.6), and the median overall survival (OS) was 22.3 months (95% CI: 17.5-27.2). In multivariate analysis, serous histological type (P = 0.01), maintenance BEV administration (P = 0.001), and combination of GC-BEV (P < 0.001) were associated with better PFS, while serous histological type (P = 0.016) and good performance status (P = 0.006) were associated with prolonged OS.
    Conclusions: Low-dose (7.5 mg/kg) BEV was found to be effective in the second-line treatment of patients with ROC in our real-life study. In addition, the combination of BEV with GC was shown to be a viable option, especially in the treatment selection of platinum-resistant patients.
    MeSH term(s) Humans ; Female ; Bevacizumab ; Retrospective Studies ; Carboplatin ; Ovarian Neoplasms/pathology ; Vascular Endothelial Growth Factor A ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Neoplasm Recurrence, Local/pathology ; Carcinoma, Ovarian Epithelial/drug therapy
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; Carboplatin (BG3F62OND5) ; Vascular Endothelial Growth Factor A
    Language English
    Publishing date 2023-07-20
    Publishing country India
    Document type Journal Article
    ZDB-ID 2187633-2
    ISSN 1998-4138 ; 0973-1482
    ISSN (online) 1998-4138
    ISSN 0973-1482
    DOI 10.4103/jcrt.jcrt_1879_20
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Serum chromogranin A levels are associated with the SYNTAX score in coronary artery disease.

    Çelikkol, Aliye / Demirkıran, Aykut / Aydın, Cihan / Akyüz, Aydın / Kaplangöray, Mustafa / Yılmaz, Ahsen / Efe, Muhammed Mucip / Güzel, Savaş

    Revista da Associacao Medica Brasileira (1992)

    2023  Volume 69, Issue 4, Page(s) e20221254

    Abstract: Objective: In this article, we investigated the association of chromogranin A with coronary artery disease.: Methods: Biochemical parameters and chromogranin A levels obtained from peripheral blood samples during coronary angiography were analyzed in ...

    Abstract Objective: In this article, we investigated the association of chromogranin A with coronary artery disease.
    Methods: Biochemical parameters and chromogranin A levels obtained from peripheral blood samples during coronary angiography were analyzed in 90 patients. Patients were classified into two groups, namely, SYNergy between PCI with TAXUS and Cardiac Surgery score ≥1 (n=45) and SYNergy between PCI with TAXUS and Cardiac Surgery score=0 (n=45). This is a cross-sectional, prospective study.
    Results: Serum chromogranin A levels were significantly higher in the group with SYNergy between PCI with TAXUS and Cardiac Surgery score ≥1 compared to the group with SYNergy between PCI with TAXUS and Cardiac Surgery score=0 (1381.5±418.9 ng/mL and 1121.2±290.7 ng/mL, respectively; p=0.002). Serum chromogranin A levels were correlated with SYNergy between PCI with TAXUS and Cardiac Surgery score (r=0.556, p<0.04). ROC analysis showed that the area under the curve for serum chromogranin A levels was 0.687 (p=0.007), and the best cutoff value of 1,131 ng/mL had a sensitivity of 67% and a specificity of 65% for the prediction of coronary artery disease.
    Conclusion: Serum chromogranin A levels were increased in coronary artery disease patients with SYNergy between PCI with TAXUS and Cardiac Surgery score ≥1. Increasing serum chromogranin A levels are proportional to the SYNergy between PCI with TAXUS and Cardiac Surgery score.
    MeSH term(s) Humans ; Coronary Artery Disease/diagnostic imaging ; Coronary Artery Disease/surgery ; Chromogranin A ; Coronary Artery Bypass ; Percutaneous Coronary Intervention ; Prospective Studies ; Cross-Sectional Studies ; Treatment Outcome ; Risk Factors ; Coronary Angiography
    Chemical Substances Chromogranin A
    Language English
    Publishing date 2023-04-14
    Publishing country Brazil
    Document type Journal Article
    ZDB-ID 731969-1
    ISSN 1806-9282 ; 0104-4230 ; 0004-5241 ; 0102-843X
    ISSN (online) 1806-9282
    ISSN 0104-4230 ; 0004-5241 ; 0102-843X
    DOI 10.1590/1806-9282.20221254
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 654: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy?

    Korkmaz, Mustafa / Eryılmaz, Melek K / Koçak, Mehmet Z / Er, Muhammed M / Hendem, Engin / Demirkıran, Aykut / Araz, Murat / Karaağaç, Mustafa / Artaç, Mehmet

    Journal of cancer research and therapeutics

    2023  Volume 19, Issue Supplement, Page(s) S0

    Abstract: Aim: It is red cell distribution width (RDW) that has been reported to show an inflammatory response which has been studied recently. The aim of this study is to investigate whether the pre-treatment RDW in patients using first-line vascular endothelial ...

    Abstract Aim: It is red cell distribution width (RDW) that has been reported to show an inflammatory response which has been studied recently. The aim of this study is to investigate whether the pre-treatment RDW in patients using first-line vascular endothelial growth factor tyrosine kinase inhibitor (VEGFR TKI) with the diagnosis of metastatic renal cell carcinoma (mRCC) predicts treatment response and is a prognostic factor or not.
    Methods: About 92 patients diagnosed with mRCC who were being treated with sunitinib or pazopanib in the first line between January 2015 and June 2021 were included in the study. The patients were divided into 2 groups, as being ≤15.3 and >15.3, according to the RDW cut-off value calculated by ROC analysis.
    Results: The mOS of patients with a RDW of ≤15.3% was 45.0 (30.0-59.9) months, and of 21.3 (10.4-32.2) in those with a RDW of >15.3%. This difference was statistically significant (p < 0.001). In the group of patients with a RDW of ≤15.3, median progression free survival (mPFS) (38.04 [16.3-59.7] months) was found to be significantly higher than those with a RDW of >15.3 (17.1 [11.8-22.5] months) (p = 0.04). In multivariate analysis, RDW level (≤15.3, >15.3), was determined to be prognostic markers (p = 0.022).
    Conclusion: In mRCC patients, the RDW value measured before first-line VEGFR TKI therapy is an independent prognostic marker.
    MeSH term(s) Humans ; Carcinoma, Renal Cell/pathology ; Vascular Endothelial Growth Factor A ; Tyrosine Kinase Inhibitors ; Kidney Neoplasms/pathology ; Erythrocyte Indices ; Protein Kinase Inhibitors ; Prognosis ; Angiogenesis Inhibitors/therapeutic use ; Receptors, Vascular Endothelial Growth Factor ; Erythrocytes ; Retrospective Studies
    Chemical Substances Vascular Endothelial Growth Factor A ; Tyrosine Kinase Inhibitors ; Protein Kinase Inhibitors ; Angiogenesis Inhibitors ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1)
    Language English
    Publishing date 2023-05-06
    Publishing country India
    Document type Journal Article
    ZDB-ID 2187633-2
    ISSN 1998-4138 ; 0973-1482
    ISSN (online) 1998-4138
    ISSN 0973-1482
    DOI 10.4103/jcrt.jcrt_898_22
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top